Quest Diagnostics Incorporated DGX
236.32
(0.27)
(0.11%)
as of 25 Sep
- Market cap
- $26.2B
- P/E
- 24.8×
Follow DGX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| P/E ratio | 22.22 | 21.37 | 19.56 | 22.06 |
+8 more quarters Free account |
| P/S ratio | 2.04 | 1.91 | 1.75 | 1.97 | |
| P/FCF ratio | 17.44 | 16.26 | 14.17 | 15.32 | |
| P/Operating CF | 39.41 | 77.55 | 41.42 | 37.91 | |
| P/B ratio | 3.01 | 2.81 | 2.67 | 2.93 | |
| Price to Tangible BV | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/Sales | 2.47 | 2.38 | 2.22 | 2.45 | |
| EV/EBITDA | 12.92 | 12.27 | 11.53 | 12.72 | |
| EV/Operating CF | 15.00 | 14.50 | 13.00 | 14.11 | |
| EV/FCF | 21.16 | 20.23 | 18.04 | 19.09 | |
| Quick Ratio | 1.28 | 0.91 | 0.80 | 0.88 | |
| Current Ratio | 1.59 | 1.18 | 1.04 | 1.13 | |
| Net Debt/EBITDA | 8.29 | 9.64 | 9.89 | 9.93 | |
| Debt/Assets | 33.31% | 33.94% | 34.95% | 35.04% | |
| Debt/Equity | 0.72 | 0.74 | 0.79 | 0.78 | |
| Asset Turnover | 0.70 | 0.69 | 0.68 | 0.67 | |
| Operating CF/Net income | 1.87 | 1.10 | 1.93 | 2.30 | |
| Capex/Depreciation | (0.95) | (0.78) | (1.09) | (1.01) | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Selling, General and Administrative Expense of Revenue | 17.38% | 17.41% | 17.96% | 17.79% | |
| Intangible Assets out of Total Assets | 0.64 | 0.65 | 0.65 | 0.65 | |
| Share Based Compensation of Revenue | 0.76% | 0.69% | 0.89% | 0.71% | |
| Graham Net Nets | (0.27) | (0.30) | (0.34) | (0.30) | |
| Graham Number | 122.96 | 119.91 | 113.83 | 112.53 | |
| Earnings Yield | 4.50% | 4.68% | 5.11% | 4.53% | |
| Free Cash Flow Yield | 5.73% | 6.15% | 7.06% | 6.53% | |
| Revenue per Share | 27.41 | 26.32 | 25.28 | 25.14 | |
| Operating CF per Share | 5.38 | 2.53 | 4.19 | 5.03 | |
| Capex per Share | (1.24) | (1.04) | (1.42) | (1.29) | |
| Free Cash Flow per Share | 4.14 | 1.49 | 2.77 | 3.74 | |
| Cash per Share | 5.64 | 3.57 | 3.78 | 3.86 | |
| Shareholders Equity per Share | 70.44 | 69.69 | 64.92 | 65.13 | |
| Interest Debt per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book value per Share | 70.44 | 69.69 | 64.92 | 65.13 | |
| Free Cash Flow | 459.00 | 164.00 | 307.00 | 419.00 | |
| Working Capital | 1,056.00 | 389.00 | 100.00 | 273.00 | |
| Capital Expenditures | (138.00) | (114.00) | (158.00) | (144.00) | |
| Net Current Asset Value | (6,276.00) | (6,441.00) | (6,641.00) | (6,495.00) | |
| EV/EBIT | 17.51 | 16.67 | 15.75 | 17.37 | |
| Capex to Sales | 0.05 | 0.04 | 0.06 | 0.05 | |
| Net Profit Margin | 10.52% | 8.70% | 8.59% | 8.70% | |
| Price to Operating Income | 14.43 | 13.40 | 12.38 | 13.94 | |
| Other line items | |||||
| Average Receivables | 1,542.50 | 1,495.50 | 1,356.00 | 1,416.00 | |
| Average Payables | 1,473.50 | 1,383.50 | 1,497.00 | 1,385.00 | |
| Average Inventory | 210.00 | 207.00 | 188.50 | 185.00 | |
| Average Assets | 16,454.00 | 16,235.00 | 16,189.00 | 16,146.00 | |
| Average Common Equity | 7,542.00 | 7,314.00 | 7,009.50 | 7,068.00 |
Columns are period end dates